{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:24:02Z","timestamp":1790871842779,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"\n Introduction:<\/jats:title>\n Remdesivir, an antiviral drug, received an emergency use authorization for treating coronavirus disease 2019 (COVID-19) patients. Though many studies have reported the safety aspects of this antiviral agent, most of them were observed in severely ill COVID-19 patients, making very less data available in the moderately ill patients. The present study was conducted with an objective of finding the adverse events (AEs) associated with remdesivir in moderately ill COVID-19 patients.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n A retrospective observational study was conducted by collecting data of demographic details and details of remdesivir, laboratory investigations, and AEs from the patient medical records from May to July 2021 and analyzed by using the appropriate statistics.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Out of the 160 COVID-19 patients, 32 were moderately ill (males: 29, females: 03) and were treated with remdesivir along with steroids and low molecular weight heparin (LMW) heparin. The average number of administered remdesivir doses was 4, with a loading dose of 200 mg and a maintenance dose of 100 mg. A total of 41 AEs were observed out of which 17 were adverse drug reactions (ADRs) (a significant increase in the alanine transaminase (ALT) [\n P<\/jats:italic>\n < 0.001]) and 23 AEs (a significant rise in random blood sugars, RBS [one of the AEs] [\n P<\/jats:italic>\n = 0.007]). The AEs were more commonly seen in the hypertensive patients. An increased oxygen requirement was a major serious AE observed in four patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Remdesivir caused a significant increase in the liver enzymes. Increased blood sugar levels were the most common AE and increased oxygen requirement was the major serious AE observed.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_2468_21","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:11:16Z","timestamp":1659330676000},"page":"3693-3698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis"],"prefix":"10.4103","volume":"11","author":[{"given":"Ravi","family":"Gandham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Eerike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Bisoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Priyadarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-48-20240828","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection:Origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J Adv Res"},{"key":"R3-48-20240828","doi-asserted-by":"crossref","first-page":"107232","DOI":"10.1016\/j.intimp.2020.107232","article-title":"A comparative analysis for anti-viral drugs:Their efficiency against SARS-CoV-2","volume":"90","author":"Kivrak","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R4-48-20240828","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19:A randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"R5-48-20240828","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir:First approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"R8-48-20240828","doi-asserted-by":"crossref","first-page":"110532","DOI":"10.1016\/j.biopha.2020.110532","article-title":"Safety profile of the antiviral drug remdesivir: An update","volume":"130","author":"Fan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R9-48-20240828","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-48-20240828","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID- 19:A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"R11-48-20240828","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/14740338.2021.1962846","article-title":"Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data","volume":"20","author":"Singh","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"R17-48-20240828","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12072-020-10077-3","article-title":"Liver injury in remdesivir-treated COVID-19 patients","volume":"28","author":"Zampino","year":"2020","journal-title":"Hepatol Int"},{"key":"R18-48-20240828","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1111\/bcp.14831","article-title":"Liver and kidney function in patients with COVID-19 treated with remdesivir","volume":"87","author":"Van Laar","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R19-48-20240828","doi-asserted-by":"crossref","first-page":"731436","DOI":"10.3389\/fmed.2021.731436","article-title":"Drug-induced liver injury in COVID-19 patients:A systematic review","volume":"8","author":"Sodeifian","year":"2021","journal-title":"Front Med (Lausanne"},{"key":"R20-48-20240828","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40264-020-00954-z","article-title":"Drug-induced liver injury and COVID-19 infection:The rules remain the same","volume":"43","author":"Olry","year":"2020","journal-title":"Drug Saf"},{"key":"R21-48-20240828","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4254\/wjh.v13.i9.1143","article-title":"Drug-induced liver injury and COVID-19:A review for clinical practice","volume":"13","author":"Xavier Ortiz","year":"2021","journal-title":"World J Hepatol"},{"key":"R22-48-20240828","first-page":"235","article-title":"Post-COVID-19 hyperglycemia:A concern in selection of therapeutic regimens","volume":"46","author":"Negahdaripour","year":"2021","journal-title":"Iran J Med Sci"},{"key":"R23-48-20240828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5501\/wjv.v10.i5.275","article-title":"New-onset diabetes in COVID-19 and clinical outcomes:A systematic review and meta-analysis","volume":"10","author":"Shrestha","year":"2021","journal-title":"World J Virol"},{"key":"R24-48-20240828","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19-Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R26-48-20240828","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"key":"R27-48-20240828","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/ejhpharm-2020-002613","article-title":"A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine:A preliminary report","volume":"28","author":"Falcao","year":"2021","journal-title":"Eur J Hosp Pharm"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2468_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:07:50Z","timestamp":1787756870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2468_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2468_21","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}